GALAPAGOS NV/S (NASDAQ:GLPG) Upgraded by BidaskClub to “Hold”

Share on StockTwits

BidaskClub upgraded shares of GALAPAGOS NV/S (NASDAQ:GLPG) from a sell rating to a hold rating in a research note issued to investors on Friday, October 19th.

Other research analysts have also recently issued reports about the company. Zacks Investment Research cut GALAPAGOS NV/S from a buy rating to a hold rating in a report on Wednesday, July 4th. Credit Suisse Group set a $92.00 price objective on GALAPAGOS NV/S and gave the company a hold rating in a report on Tuesday, August 7th. Stifel Nicolaus cut their target price on GALAPAGOS NV/S from $120.00 to $109.00 and set a buy rating on the stock in a research report on Friday, June 29th. Goldman Sachs Group lowered GALAPAGOS NV/S from a buy rating to a neutral rating in a research report on Thursday, August 9th. Finally, Royal Bank of Canada cut their target price on GALAPAGOS NV/S to $94.00 and set a sector perform rating on the stock in a research report on Friday, June 29th. Four research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. GALAPAGOS NV/S has an average rating of Buy and an average price target of $117.00.

Shares of GALAPAGOS NV/S stock traded down $1.42 on Friday, hitting $105.99. 81,297 shares of the company were exchanged, compared to its average volume of 144,759. GALAPAGOS NV/S has a 1-year low of $84.13 and a 1-year high of $122.28. The stock has a market cap of $5.59 billion, a P/E ratio of -40.15 and a beta of 1.91.

Several institutional investors have recently bought and sold shares of GLPG. Federated Investors Inc. PA increased its holdings in GALAPAGOS NV/S by 9.3% in the second quarter. Federated Investors Inc. PA now owns 1,424,763 shares of the biotechnology company’s stock valued at $131,335,000 after buying an additional 121,415 shares during the last quarter. BlackRock Inc. increased its holdings in GALAPAGOS NV/S by 18.4% in the third quarter. BlackRock Inc. now owns 365,413 shares of the biotechnology company’s stock valued at $41,083,000 after buying an additional 56,848 shares during the last quarter. Peregrine Capital Management LLC increased its holdings in GALAPAGOS NV/S by 5.4% in the second quarter. Peregrine Capital Management LLC now owns 107,675 shares of the biotechnology company’s stock valued at $9,925,000 after buying an additional 5,539 shares during the last quarter. Dorsey Wright & Associates increased its holdings in GALAPAGOS NV/S by 9.1% in the second quarter. Dorsey Wright & Associates now owns 98,544 shares of the biotechnology company’s stock valued at $9,312,000 after buying an additional 8,186 shares during the last quarter. Finally, Alps Advisors Inc. increased its holdings in GALAPAGOS NV/S by 23.8% in the third quarter. Alps Advisors Inc. now owns 90,848 shares of the biotechnology company’s stock valued at $10,214,000 after buying an additional 17,459 shares during the last quarter. 14.54% of the stock is currently owned by institutional investors and hedge funds.

About GALAPAGOS NV/S

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: Fiduciary

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.